ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

TAK Takeda Pharmaceutical Company Ltd

13.27
0.00 (0.00%)
Pre Mercado
Última actualización: 04:22:35
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Takeda Pharmaceutical Company Ltd TAK NYSE Certificado de Depósito
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.00 0.00% 13.27 04:22:35
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
13.27
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
26/4/202407:30BWTakeda Receives Positive CHMP Opinion for Fruquintinib in..
23/4/202406:00PRNUSNeurocrine Biosciences Reports Positive Phase 2 Data for..
22/4/202403:10PRNUSTakeda, Astellas and Sumitomo Mitsui Banking Announce Master..
18/4/202418:00BWU.S. FDA Approves Subcutaneous Administration of Takeda’s..
08/4/202407:00BWTakeda Announces New U.S. Corporate Social Responsibility..
27/3/202407:56PRNUSEmpathy in Action: Takeda's Global Initiative Brings IBD..
27/3/202407:53PRNUSEmpathy in Action: Takeda's Global Initiative Brings IBD..
27/3/202400:01BWTakeda gibt Kandidaten für den Vorstand bei der kommenden..
26/3/202418:07BW武田薬品工業: 第148回定時株主総会に提案する取締役候補者について
26/3/202407:00BWTakeda Announces Approval of ADZYNMA® Intravenous Injection..
21/3/202408:39BW武田薬品、Ph+..
21/3/202402:33BWTakeda meldet sNDA-Zulassung von ICLUSIG® (Ponatinib) durch..
20/3/202414:18BWTakeda annonce l'approbation par la FDA des États-Unis d'une..
19/3/202411:20BWTakeda Announces U.S. FDA Approval of Supplemental New Drug..
19/3/202405:30GLOBECENTOGENE Extends Strategic Partnership With Takeda to..
13/3/202407:00BWTakeda Announces Positive Topline Results from Phase 2 Study..
28/2/202406:03BW武田薬品とBiological E. Limited、デング熱流行地域におけるワクチンへのアクセス促進で協力
27/2/202416:26BWTakeda et Biological E. Limited s’associent pour accélérer..
27/2/202406:38BWTakeda und Biological E. Limited arbeiten zusammen, um den..
26/2/202422:30BWTakeda and Biological E. Limited Collaborate to Accelerate..
26/2/202406:00PRNCAChampioning Rare Voices on Rare Disease Day
12/2/202407:00BWFDA Approves Takeda’s EOHILIA (budesonide oral suspension),..
08/2/202417:00BWTakeda Intends to Rapidly Initiate the First Global Phase 3..
01/2/202415:23BWTakeda gibt Nachfolger für die Position des Chief Financial..
01/2/202415:18BWTakeda annonce la succession de son directeur financier
01/2/202408:59BWTakeda gibt Ergebnisse für das dritte Quartal des..
01/2/202405:18EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/2/202405:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/2/202400:54BWTakeda Announces Chief Financial Officer Succession
01/2/202400:02BWTakeda Announces Third-Quarter FY2023 Results; On-Track..
30/1/202410:00BW武田薬品、慢性炎症性脱髄性多発根神経炎(CIDP)に対する維持療法としてのHYQVIA®について、欧州委員会から承認を獲得
30/1/202407:04BWTakeda-Arzneimittel HYQVIA ® von der Europäischen Kommission..
29/1/202412:55BWLe HYQVIA® de Takeda approuvé par la Commission européenne..
29/1/202410:10BWTakeda’s GAMMAGARD LIQUID® Approved by U.S. FDA for Adults..
29/1/202401:00BWTakeda’s HYQVIA® Approved by European Commission as..
25/1/202416:00PRNUSCognizant Helping to Modernize Infrastructure and..
25/1/202405:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/1/202405:11EDGAR2Form SC 13D/A - General statement of acquisition of..
19/1/202405:03EDGAR2Form SC 13G - Statement of acquisition of beneficial..
18/1/202412:56BWTakeda est nommée Top Employer mondial pour la septième..
18/1/202412:45BW武田薬品工業、7年連続でトップ・エンプロイヤーに認定
18/1/202412:22BWTakeda im siebten Jahr in Folge international als Top..
18/1/202406:00BWTakeda Named Global Top Employer for Seventh Consecutive..
16/1/202407:00BWU.S. FDA Approves Takeda’s HYQVIA® as Maintenance Therapy in..
16/1/202405:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/12/202315:00BWTakeda Announces China NMPA Approval of LIVTENCITY®..
20/12/202306:01PRNCATakeda Enters Into Two-Year Contract with Canadian Blood..
16/12/202310:36BWTakeda obtient l’avis favorable du CHMP pour HYQVIA® en tant..
16/12/202309:47BWTakeda erhält positive CHMP-Stellungnahme für HYQVIA® als..
15/12/202307:16BWTakeda Receives Positive CHMP Opinion for HYQVIA® as..

Su Consulta Reciente

Delayed Upgrade Clock